Skip to content
10-Q

Quarterly Report

Keenova Therapeutics plc

0001628280-25-051167

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 7, 2025 39.53M sh
Shares Diluted Q3 2025 · Sep 26, 2025 32.3M sh
Shares Diluted Q3 2025 · Sep 26, 2025 23.9M sh
Shares Diluted Q3 2025 · Sep 27, 2024 19.7M sh
Shares Diluted Q3 2025 · Sep 27, 2024 19.7M sh
Stock Repurchased Q3 2025 · Sep 26, 2025 $1.9M
Stock Repurchased Q3 2025 · Sep 27, 2024 $0
Capex Q3 2025 · Sep 26, 2025 $70.8M
Capex Q3 2025 · Sep 27, 2024 $71.5M
Operating Cash Flow Q3 2025 · Sep 26, 2025 $126.4M
Operating Cash Flow Q3 2025 · Sep 27, 2024 $185.7M
Short Term Debt Q3 2025 · Sep 26, 2025 $37.5M
Short Term Debt Q3 2025 · Dec 27, 2024 $3.9M
Cash And Equivalents Q3 2025 · Sep 26, 2025 $1.05B
Cash And Equivalents Q3 2025 · Dec 27, 2024 $382.6M
Cash And Equivalents Q3 2025 · Sep 27, 2024 $410.5M
Stockholders Equity Q3 2025 · Sep 26, 2025 $3.15B
Stockholders Equity Q3 2025 · Jun 27, 2025 $1.64B
Stockholders Equity Q3 2025 · Mar 28, 2025 $1.63B
Stockholders Equity Q3 2025 · Dec 27, 2024 $1.65B
Stockholders Equity Q3 2025 · Sep 27, 2024 $1.03B
Stockholders Equity Q3 2025 · Jun 28, 2024 $1.05B
Stockholders Equity Q3 2025 · Mar 29, 2024 $1.09B
Stockholders Equity Q3 2025 · Dec 29, 2023 $1.16B
Current Liabilities Q3 2025 · Sep 26, 2025 $1.07B
Current Liabilities Q3 2025 · Dec 27, 2024 $431.4M
Total Liabilities Q3 2025 · Sep 26, 2025 $5.32B
Total Liabilities Q3 2025 · Dec 27, 2024 $1.66B
Current Assets Q3 2025 · Sep 26, 2025 $3.46B
Current Assets Q3 2025 · Dec 27, 2024 $1.63B
Total Assets Q3 2025 · Sep 26, 2025 $8.47B
Total Assets Q3 2025 · Dec 27, 2024 $3.3B
Eps Diluted Q3 2025 · Sep 26, 2025 −$9.01
Eps Diluted Q3 2025 · Sep 26, 2025 −$13.24
Eps Diluted Q3 2025 · Sep 27, 2024 −$1.33
Eps Diluted Q3 2025 · Sep 27, 2024 −$6.85
Eps Basic Q3 2025 · Sep 26, 2025 −$9.01
Eps Basic Q3 2025 · Sep 26, 2025 −$13.24
Eps Basic Q3 2025 · Sep 27, 2024 −$1.33
Eps Basic Q3 2025 · Sep 27, 2024 −$6.85
Sga Expense Q3 2025 · Sep 26, 2025 $351.7M
Sga Expense Q3 2025 · Sep 26, 2025 $649.8M
Sga Expense Q3 2025 · Sep 27, 2024 $141.2M
Sga Expense Q3 2025 · Sep 27, 2024 $406M
Rd Expense Q3 2025 · Sep 26, 2025 $44.3M
Rd Expense Q3 2025 · Sep 26, 2025 $88.4M
Rd Expense Q3 2025 · Sep 27, 2024 $28.2M
Rd Expense Q3 2025 · Sep 27, 2024 $85.3M
Net Income Q3 2025 · Sep 26, 2025 −$291.1M
Net Income Q3 2025 · Sep 26, 2025 −$316.4M
Net Income Q3 2025 · Jun 27, 2025 $2.4M
Net Income Q3 2025 · Mar 28, 2025 −$27.7M
Net Income Q3 2025 · Sep 27, 2024 −$26.2M
Net Income Q3 2025 · Sep 27, 2024 −$134.9M
Net Income Q3 2025 · Jun 28, 2024 −$43.3M
Net Income Q3 2025 · Mar 29, 2024 −$65.4M
Operating Income Q3 2025 · Sep 26, 2025 −$269.1M
Operating Income Q3 2025 · Sep 26, 2025 −$221.1M
Operating Income Q3 2025 · Sep 27, 2024 $36.4M
Operating Income Q3 2025 · Sep 27, 2024 $46.1M
Gross Profit Q3 2025 · Sep 26, 2025 $254M
Gross Profit Q3 2025 · Sep 26, 2025 $688.7M
Gross Profit Q3 2025 · Sep 27, 2024 $221.1M
Gross Profit Q3 2025 · Sep 27, 2024 $580.1M
Cost Of Revenue Q3 2025 · Sep 26, 2025 $499.1M
Cost Of Revenue Q3 2025 · Sep 26, 2025 $969.4M
Cost Of Revenue Q3 2025 · Sep 27, 2024 $284.4M
Cost Of Revenue Q3 2025 · Sep 27, 2024 $907.5M
Revenue Q3 2025 · Sep 26, 2025 $753.1M
Revenue Q3 2025 · Sep 26, 2025 $1.66B
Revenue Q3 2025 · Sep 27, 2024 $505.5M
Revenue Q3 2025 · Sep 27, 2024 $1.49B